Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-08-11
- Lead Sponsor
- Akeso
- Target Recruit Count
- 130
- Registration Number
- NCT05235542
- Locations
- 🇨🇳
Shanghai Renji Hospital, Shanghai, China
Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC
- Conditions
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 44
- Registration Number
- NCT05229003
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
- Conditions
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Ludwig-Maximilians - University of Munich
- Target Recruit Count
- 57
- Registration Number
- NCT05217069
- Locations
- 🇩🇪
Ludwig Maximilians University, Munich, Germany
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 140
- Registration Number
- NCT05178745
Selinexor Combination Ph 1 Study
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2022-01-04
- Lead Sponsor
- Martin Gutierrez
- Registration Number
- NCT05177276
- Locations
- 🇺🇸
John Theurer Cancer Center at HackensackUMC, Hackensack, New Jersey, United States
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2023-06-08
- Target Recruit Count
- 90
- Registration Number
- NCT05160896
- Locations
- 🇨🇳
the Second Affiliated Hospital of Medical College of Zhejiang University, Hangzhou, Zhejiang, China
Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2021-12-20
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT05160727
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
- Conditions
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 705
- Registration Number
- NCT05153239
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇨🇱Clinical Research Chile SpA, Valdivia, Los Ríos, Chile
🇨🇭University Hospital Basel, Basel, Switzerland
A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT05148195
- Locations
- 🇨🇳
Sun Yat-sen University affiliated with the Sixth Hospital, Guangzhou, China
🇨🇳Shaw Hospital Affiliated to Medical College of Zhejiang Universit, Hangzhou, China
🇨🇳Beijing Cancer Hospital, Beijing, China
CtDNA-Directed Post-Hepatectomy Chemotherapy for Patients with Resectable Colorectal Liver Metastases
- Conditions
- Interventions
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 120
- Registration Number
- NCT05062317
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.